Data Support Further Development of CYT-338 in Relapsed/Refractory Multiple Myeloma | Antibody

Data support further development of CYT-338 in relapsed/refractory multiple myeloma

AVENTURA, FL and NATICK, MA, USA I June 10, 2022 I Cytovia Therapeutics, Inc., a biopharmaceutical company enabling natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that new data it is presenting at the annual meeting of the European Hematology Association in Vienna, Austria on June 10e2022 is now available on the EHA and Cytovia websites.

For more details on in-person poster presentations, please see the following:

Session Title: Poster Session
Session date and time: Friday, June 10, 2022 – 4:30 p.m. – 5:45 p.m. CEST
Final abstract code: P842
Abstract link: 2Abrowseby %3D8%2Atrierby%3D1%2Asearch%3DNK

Summary: CYT-338 is a multifunctional tetravalent IgG1-like NK cell-engaging antibody with a novel FLEX linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46. The pharmacokinetics and pharmacodynamics of CYT-338 have been studied using in vitro and in vivo multiple myeloma models. CYT-338 showed 3-fold higher dose-dependent binding to CD38-expressing MM cell lines compared to daratumumab. Epitope mapping studies indicated that CYT-338 binds to a different CD38 epitope than daratumumab. CYT-338 showed greater dose-dependent cytolysis, degranulation, and NK cell-redirected cytokine production against MM1S cells compared to daratumumab. CYT-338 showed minimal immune subset depletion, NK cell fratricidal, and cytokine release compared to daratumumab in vitro. CYT-338 has been shown to inhibit tumor growth and improve survival in in vivo models of multiple myeloma. These results support the further development of CYT-338 as a therapeutic to target CD38 expressing multiple myeloma cells distinct from daratumumab.

About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing many of the most challenging unmet medical needs in cancer. Cytovia is focused on harnessing the innate immune system by developing complementary and disruptive NK cell and NK-engaging antibody platforms. The company is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-modified iNK cells with improved function and persistence, and TALEN® gene-modified iNK cells with chimeric antigen receptors (CAR-iNK) to improve specific tumor targeting. The second complementary core technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology.

These two technology platforms are used to develop treatments for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.

Based in Aventura, Florida, Cytovia has research and development labs in Natick, Massachusetts and a GMP cell manufacturing facility in Puerto Rico. The company’s R&D work is complemented by scientific partnerships with Cellectis, CytoImmune, Hebrew University of Jerusalem, INSERM, New York Stem Cell Foundation and University of California, San Francisco (UCSF).

Cytovia recently formed CytoLynx Therapeutics, a strategic partnership focused on research and development, manufacturing and commercialization activities in Greater China and beyond.

Learn more about and follow us on Facebook, Twitter, LinkedIn, Youtubeand instagram.

About CD38
Differentiation cluster 38 (CD38) is a type II receptor membrane glycoprotein that plays a role in cell adhesion, migration, and signal transduction. Moreover, CD38 is an ectoenzyme involved in the generation of nucleotide metabolites, such as ADP-ribose which regulate cellular metabolism. CD38 is highly expressed in multiple myeloma (MM) on malignant plasma cells and is also moderately expressed on normal T, B, NK and myeloid cells. Antibodies targeting CD38, such as daratumumab and isatuximab, are FDA-approved for the treatment of MM as monotherapy and in combination.

THE SOURCE: Cytovia therapeutics

Comments are closed.